Skip to main content
ContextVision AB logo

ContextVision AB — Investor Relations & Filings

Ticker · CONTX ISIN · SE0014731154 LEI · 549300DGJB24U1VKHC98 OL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2021-11-15 Proxy Solicitation & In…
Country SE Sweden
Listing OL CONTX

About ContextVision AB

https://www.contextvision.se/

ContextVision is a medical technology software company specializing in image analysis and artificial intelligence. As a global market leader in image enhancement, it provides advanced software solutions to Original Equipment Manufacturers (OEMs) of medical imaging systems. The company's technology enhances image quality for modalities such as ultrasound, X-ray, and MRI, enabling faster and more reliable clinical diagnoses. Its versatile post-processing software is customized for each system to ensure optimal performance and is installed in over 400,000 systems globally. ContextVision is expanding its offerings with a modular ultrasound platform and is actively involved in developing diagnostic tools for digital pathology and liver disease.

Recent filings

Filing Released Lang Actions
NOTICE TO EXTRAORDINARY GENERAL MEETING IN CONTEXTVISION AB (PUBL)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice to Extraordinary General Meeting' (EGM) for ContextVision AB. It contains the agenda, instructions for shareholder participation, voting procedures, and the board's specific proposals (including a dividend distribution of a subsidiary). This document is provided to shareholders to inform them of the meeting and solicit their participation and votes. According to the filing definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI).
2021-11-15 English
ContextVision to focus pathology efforts on the establishment of a fully AI-supported lab service
Regulatory Filings Classification · 1% confidence The document is a press release announcing a significant strategic shift in the company's business model (moving from selling software tools to establishing an AI-based lab service). It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a general corporate announcement regarding business strategy and operations, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for material corporate disclosures.
2021-11-15 English
ContextVision vil fokusere patologiinnsatsen på etableringen av en fullt AI-støttet laboratorietjeneste
Regulatory Filings Classification · 1% confidence The document is a press release from ContextVision announcing a major strategic shift in their business model (focusing on AI-based laboratory services). It is not a financial report, audit, or proxy statement. It functions as a corporate announcement regarding business strategy and operations, which falls under the 'Regulatory Filings' (RNS) category as it is a mandatory disclosure under the Norwegian Securities Trading Act (verdipapirhandelloven §5-12) and EU Market Abuse Regulation.
2021-11-15 Norwegian
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for ContextVision AB covering the third quarter of 2021. It includes detailed financial data, such as income statements, balance sheet information, management commentary, and segment reporting. It is clearly an interim financial report rather than an announcement or a summary, as it contains 13 pages of detailed financial disclosures and analysis. Q3 2021
2021-10-21 English
ContextVision - INIFY results from a US clinical evaluation
Regulatory Filings Classification · 1% confidence The document is a press release announcing clinical study results for a medical software product (INIFY Prostate). It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it represent a corporate action like a dividend or share issue. As it is a general corporate announcement regarding product development and clinical validation, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate news disclosures.
2021-10-18 English
ContextVision - Mandatory notification of trade September 1
Director's Dealing Classification · 1% confidence The document is a mandatory notification of a trade by a primary insider (a member of the Board of Directors). It explicitly details the purchase of 6,000 shares by Martin Ingvar, including the transaction date, price, and post-transaction holdings. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2021-09-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.